CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Investor Relations  /  Stock Exchange Disclosures  /  Announcements & Disclosures

OTHER ANNOUNCEMENTS & DISCLOSURES

FY 2025 - 26

June-25
26-Jun Intimation regarding closure of Trading Window
26-Jun Disclosure under Regulation 30 of the SEBI Listing Regulations.
26-Jun Communication to the shareholders w.r.t. TDS on Final Dividend
19-Jun Disclosure of the details of allotment in the Issue (as defined hereinafter) by the Biocon Limited (the “Company”) in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements), 2015, as amended (“SEBI Listing Regulations”).
19-Jun Qualified Institutions Placement of equity shares of face value ₹ 5 each (“Equity Shares”) (such placement, the “Issue”) by Biocon Limited (the “Company”) under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”) and Sections 42, 23(1)(b) and 62(1)(c) of the Companies Act, 2013, as amended.
19-Jun Qualified Institutions Placement of equity shares of face value ₹ 5 each (“Equity Shares”) (such placement, the “Issue”) by Biocon Limited (the “Company”) under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and Sections 42, 23(1)(b) and 62(1)(c) of the Companies Act, 2013, as amended.
18-Jun Intimation regarding Credit Rating
16-Jun Qualified Institutions Placement of equity shares of face value ₹ 5 each (“Equity Shares”) (such placement, the “Issue”) by Biocon Limited (the “Company”) under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and Sections 42, 23(1)(b) and 62(1)(c) of the Companies Act, 2013, as amended.
16-Jun Intimation of the approval of the audited consolidated financial statements for the financial year ended March 31, 2025.
04-Jun Voting results and Scrutinizers Report on Postal Ballot
May-25
27-May Reminder Letter to holders of physical securities for furnishing of KYC details
15-May Q4 FY25 – Earnings Call Transcript
13-May Reminder Letter to shareholders to claim unclaimed dividends.
12-May Annual Secretarial Compliance Report
12-May Q4 FY25 – Corporate Presentation
09-May Q4 FY25 – Earnings Call Audio and Video Recording Link
09-May Q4 FY25 – Earnings Call Presentation
08-May Outcome of the Board Meeting
05-May Postal Ballot Notice
Apr-25
30-Apr Record Date Intimation for Commercial Papers
29-Apr Redemption of Commercial Papers
23-Apr Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
22-Apr Issue of Commercial Papers of Rs. 600 Crores
15-Apr Intimation regarding Credit Rating
14-Apr Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2025
14-Apr Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2025
10-Apr Certificate pursuant to SEBI Master Circular no. SEBI/HO/DDHS/PoD1/P/CIR/2024/54 dated May 22, 2024.
04-Apr Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
01-Apr Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

FY 2024 - 25

Mar-25
29-Mar Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
28-Mar Reminder Letter to shareholders for claiming Unclaimed dividend and Updation of KYC Information
Feb-25
26-Feb Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
18-Feb Record Date Intimation for Commercial Papers
07-Feb Q3 FY25 – Earnings Call Transcript
03-Feb Corporate Presentation
01-Feb Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Jan-25
31-Jan Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024
31-Jan Q3 FY25 – Earnings Call Audio and Video Recording Link
31-Jan Q3 FY25 – Earnings Call Presentation
30-Jan Outcome of the Board Meeting
30-Jan Intimation of Resignation – Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
30-Jan Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
29-Jan Issue of Commercial Papers of Rs. 570 Crores
27-Jan Outcome of the Board Meeting – Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
22-Jan Intimation regarding Credit Rating
09-Jan Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2024
Dec-24
30-Dec Biocon Biologics Completes Final Milestone Payments to Viatris for Acquisition
10-Dec Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Nov-24
26-Nov Intimation regarding Credit Rating
07-Nov Q2 FY25 – Earnings Call Transcript
Oct-24
31-Oct Q2 FY25 – Earnings Call Recording Link
30-Oct Q2 FY25 – Earnings Call Presentation
30-Oct Outcome of the Board Meeting
17-Oct Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2024.
14-Oct Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2024
09-Oct Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Sep-24
24-Sep Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
23-Sep Corporate Presentation – Biocon Biologics Limited
03-Sep Intimation regarding loss of Share Certificates
Aug-24
31-Aug Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
30-Aug Intimation regarding Credit Rating
28-Aug Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
23-Aug Postal Ballot Notice- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
19-Aug Q1 FY25 – Earnings Call Transcript
19-Aug Corporate Presentation
10-Aug Q1 FY25 – Earnings Call Presentation and Recording Link
09-Aug Appointment/Re-appointment of Directors at the 46th Annual General Meeting (‘AGM’) of the Company
08-Aug Outcome of the Board Meeting
July-24
25-July Completion of tenure of an Independent Director, Mr. M Damodaran.
19-July Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2024.
19-July Reminder Letter to holders of physical securities for furnishing of PAN, KYC details and Nomination details
June-24
27-June Q4 FY24 – Investor Presentation
19-June Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
14-June Clarification sought for corporate announcement filed by the Company vide its letter dated May 31, 2024
11-June Mr. Mukesh Kamath has been appointed as the Interim Chief Financial Officer and Key Managerial Personnel of the Company.
May-24
31-May Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
23-May Reminder Letter to shareholders to claim unclaimed dividends and Newspaper Advertisement in this regard.
23-May Q4 FY24 – Earnings Call Transcript
17-May Q4 FY24 – Earnings Call Presentation and Recording Link
16-May Outcome of the Board Meeting
01-May Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
April-24
30-Apr Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
25-Apr Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
15-Apr Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2024.
15-Apr Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2024
02-Apr Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

FY 2023 - 24

March-24
23-Mar Newspaper Advertisement regarding the Notice of Postal Ballot and Remote e-voting.
22-Mar Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
21-Mar Postal Ballot Notice- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
16-Mar Intimation regarding loss of Share Certificates
14-Mar Disclosure under Regulation 30 of SEBI Listing Regulations, 2015
14-Mar Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
04-Mar Mr. Vishal Nayyar is appointed as Head-Supply Chain Management, and Mr. Amit Kaptain as Head Commercials – API.
February-24
23-Feb Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Biocon Generic Inc., wholly owned step down subsidiary of the Company.
23-Feb Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
09-Feb Q3 FY24 – Investor Presentation
09-Feb Q3 FY24 – Earnings Call Presentation & Recording Link
08-Feb Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
08-Feb Outcome of the Board Meeting
07-Feb Intimation regarding Credit Rating under Regulation 30 of SEBI Listing Regulations.
January-23
11-Jan Reconciliation of Share Capital Audit Report for the quarter ended December 31, 2023.
11-Jan Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2023
December-23
20-Dec Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
13-Dec Intimation under Regulation 30 of SEBI Listing Regulations.
04-Dec Intimation regarding Issuance of ‘Letter of Confirmation’
November-23
30-Nov Intimation regarding Credit Rating under Regulation 30 of SEBI Listing Regulations
29-Nov Intimation regarding loss of Share Certificates
20-Nov Q2 FY24 – Earnings Call Transcript
17-Nov Q2 FY24 – Investor Presentation
11-Nov Intimation regarding loss of Share Certificates
11-Nov Q2 FY24 – Earnings Call Presentation & Recording Link
10-Nov Disclosure under Regulation 30 of SEBI Listing Regulations, 2015.
10-Nov Outcome of the Board Meeting
October-23
28-Oct Newspaper Advertisement regarding the Notice of Postal Ballot and Remote e-voting.
27-Oct Postal Ballot Notice- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
09-Oct Leadership Transition Announcement: Change in Head of Quality, Mr. Nitin Tiwari shall take-over from Dr. Sriram as Head – Quality w.e.f. November 01, 2023
September-23
22-Sep Disclosure under Regulation 30 of SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015
18-Sep Mr. Peter Bains Appointed as Biocon Group Chief Executive Officer
01-Sep Appointment of Non-Executive and Independent Director – Mr. Nicholas Robert Haggar
August-23
25-Aug Reporting of violations under SEBI (Prohibition of Insider Trading) Regulations, 2015.
21-Aug Disclosure pursuant to Regulation 30(4) of the SEBI Listing Regulations.
21-Aug Q1FY24 – Earnings Call Transcript
11-Aug Outcome of 45th Annual General Meeting
11-Aug Q1 FY24 – Earnings Call Presentation & Recording Link
11-Aug Q1 FY24 – Investor Presentation
10-Aug Outcome of the Board Meeting
05-Aug Intimation regarding Credit Rating under Regulation 30 of SEBI Listing Regulations.
July-23
28-July Addendum to the Notice of the 45th Annual General Meeting (AGM)
27-July Appointment of Non-Executive
and Independent Director – Ms. Rekha Mehrotra Menon
27-July Completion of tenure of an Independent Director – Dr. Vijay Kumar Kuchroo
21-July Intimation of the Q1 FY24 Earnings Call and Board Meeting
20-July Notice of 45th Annual General Meeting along with Annual Report and BRSR Report for FY 2022-23
18-July Newspaper Advertisement regarding the Notice of 45th Annual General Meeting
10-July Communication on deduction of tax at source on Final Dividend for the Financial Year ended March 31, 2023
June-23
21-June Newspaper Advertisement regarding the Notice of Postal Ballot and Remote e-voting.
20-June Postal Ballot Notice- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
May-23
31-May Q4 & FY23 Earnings Conference Call Transcript
25-May Newspaper Advertisement- Financial Results for the Quarter and Financial Year ended March 31, 2023
25-May Annual Secretarial Compliance Report for the financial year ended March 31, 2023
24-May Q4 FY23 – Earnings Call Presentation & Recording Link
24-May Q4 FY23 – Investor Presentation
23-May Outcome of the Board Meeting
May-23
19-May Allotment of Non-Convertible Debentures on private placement basis
16-May Intimation of the Q4 FY23 Earnings Call with analysts/investors under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
April-23
27-Apr Initial Disclosure to be made by an entity identified as Large Corporate as per SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.
26-Apr Outcome of Board Meeting
21-Apr Submission of amended Biocon India Limited Employees Welfare Trust Deed
18-Apr V Sreedharan & Associates – Compliance Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2023.
18-Apr V Sreedharan & Associates – Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2023
18-Apr KFin Technologies Limited – Compliance Certificate under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for year ended March 31, 2023
18-Apr KFin Technologies Limited – Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31,2023

FY 2022 - 23

February-23
22-Feb Redemption of Commercial Papers
22-Feb Q3 FY23 – Earnings Conference Call Transcript
21-Feb Allotment of Non-Convertible Debentures on private placement basis
17-Feb Q3 FY23 – Investor Presentation
16-Feb Newspaper Advertisement- Unaudited Financial Results for Quarter and nine months ended December 31, 2022
16-Feb Reminder Letter to holders of physical securities for furnishing of PAN, KYC details and nomination.
15-Feb Q3 FY23 – Investor Presentation With Earnings Call Recording Link
14-Feb Disclosure under Regulation 30 of SEBI Listing Regulations, 2015.
14-Feb Outcome of Board Meeting
13-Feb Certificate pursuant to SEBI Circular no. SEBJ/HO/DDHS/P/CIR/2021/613 dated 10th August 2021
09-Feb Record Date Intimation for Commercial Papers
08-Feb Intimation regarding Credit Rating under Regulation 30 of SEBI Listing Regulations
January-23
06-Jan Reminder Letter to shareholders for claiming unclaimed dividends
December-22
21-Dec Newspaper Advertisement regarding the Notice of Postal Ballot and Remote e-voting.
20-Dec Postal Ballot Notice- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
15-Dec Reminder Letter to shareholders and Newspaper Advertisement for claiming unclaimed dividends, whose equity shares are liable to be transferred to IEPF.
12-Dec Appointment of Independent Director – Mr. Peter Bains
01-Dec Intimation regarding Credit Rating under Regulation 30 of SEBI Listing Regulations
Novermber-22
24-Nov Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).
23-Nov Issue of Commercial Papers of Rs. 2,250 Crores
22-Nov Biocon Limited Q2FY23 Earnings Conference Call Transcript
21-Nov Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).
17-Nov Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).
17-Nov Intimation regarding Credit Rating under Regulation 30 of SEBI Listing Regulations – ICRA Limited
16-Nov Intimation regarding Credit Rating under Regulation 30 of SEBI Listing Regulations – India Ratings and Research
15-Nov Q2 FY23 – Investor Presentation With Earnings Call Recording Link
15-Nov Q2 FY23 – Investor Presentation
14-Nov Outcome of Board Meeting
09-Nov Intimation pursuant to Regulation 29(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
October-22
06-Oct Notification to Stock Exchanges on GMP inspection of an API manufacturing site in Bangalore
August-22
04-Aug Outcome of 44th Annual General Meeting
03-Aug Biocon Limited Q1FY23 Earnings Conference Call Transcript
July-22
29-July Newspaper Advertisement – Unaudited Financial Results for Quarter ended June 30, 2022
29-July Voting results and scrutinizers’ report of the 44
th Annual General Meeting (‘AGM’) of the Company
28-July Q1 FY23 – Investor Presentation With Earnings Call Recording Link
27-July Q1 FY23 – Investor Presentation
27-July Outcome of Board Meeting – Financial Results for the quarter ended June 30, 2022
21-July Notification to Stock Exchanges : pre-approval inspection for Site 3
06-July Newspaper Advertisement – Notice of the 44th Annual General Meeting, Remote E-Voting facility, cut-off date and Annual Report for the FY 2021-22 of the Company.
05-July Notice of 44th Annual General Meeting and the Annual Report for the FY 2021-22.
02-July Newspaper Advertisement – intimating that 44th Annual General Meeting of the Company will be held on Thursday, July 28, 2022 at 3.30 pm (IST).
01-July Intimation of change of date of 44th Annual General Meeting (AGM) of the Company from Friday, July 29, 2022 to Thursday, July 28, 2022
June-22
30-June Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).
May-22
11-May Annual Secretarial Compliance Report for the financial year ended March 31, 2022
06-May Q4 FY22 – Earnings Call Transcript
Apr-22
28-Apr Q4 FY22 – Investor Presentation With Earnings Call Recording Link
28-Apr Outcome of Board Meeting – Financial Results for the quarter and year ended March 31, 2022

FY 2021 - 22

Mar-22
11-Mar Intimation regarding revision in rating under Regulation 30 of SEBI Listing Regulations. – Rating Letter from ICRA
09-Mar Intimation regarding revision in rating under Regulation 30 of SEBI Listing Regulations. – Rating Letter from CRISIL
Feb-22
28-Feb Investor Presentation on “Biocon Biologics to acquire Viatris’ Biosimilars Business”.
07-Feb Biocon Pharma Limited receives U.S. FDA approval for its Posaconazole Delayed-Release tablets ANDA
Jan-22
20-Jan Q3 FY22 – Investor Presentation
20-Jan Outcome of the Board Meeting – Financial Results Q3 FY22 for the quarter and nine months ended December 31, 2021
03-Jan Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Dec-21
02-Dec Biocon Pharma Limited, a subsidiary of Biocon Limited, received approval of its ANDA for Mycophenolic Acid from the US FDA.
Nov-21
19-Nov Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club
04-Nov Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies
02-Nov Q2 FY22 – Investor Presentation
Oct-21
21-Oct Outcome of the Board Meeting – Financial Results for the quarter and half year ended September 30, 2021
04-Oct Kiran Mazumdar Shaw’s Notification to Stock Exchanges
Sep-21
30-Sep Query on announcement dated September 16, 2021, regarding merger of Covidshield Technologies Private Limited with, and into Biocon Biologics Limited.
July-21
24-July Re-appointment of Directors and Auditors of the Company
24-July Outcome of 43rd Annual General Meeting
24-July Scrutinizer’s report and Voting Results of 43rd AGM
23-July Change in Directorate of the Company.
22-July Outcome of Board Meeting – Financial Results for the quarter ended June 30, 2021;
June-21
30-June Corporate governance report for the quarter ended june 30, 2021

FY 2020 - 21

May-21
19-May Investor Presentation – Q4 FY-21
03-May Change in the name and contact details of Key Managerial Personnel under the Policy for Determination of Materiality for Disclosures.
Apr-21
28-Apr Change in Key Managerial Personnel of the Company.
28-Apr Allotment of equity shares to Biocon India Limited Employee Welfare Trust under Biocon Restricted Stock Unit Long Term Incentive Plan FY 2020-24.
28-Apr Outcome of Board Meeting – Financial Results for the quarter and year ended March 31, 2021
24-Apr Annual Secretarial Compliance Report
01-Apr Investor Presentation – Q3 FY-21
Mar-21
19-Mar Intimation for Incorporation of Wholly Owned Subsidiary Company
08-Mar Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’).
Jan-21
21-Jan Outcome of Board Meeting – Financial Results Q3 FY21 for the quarter and nine months ended December 31, 2020
Dec-20
09-Dec Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’)
Oct-20
22-Oct Outcome of Board Meeting – Financial Results for the quarter and half year ended September 30, 2020
Sep-20
22-Sep Appointment of Mr. Anupam Jindal as Chief Financial Officer and Step down of Mr. Indranil Sen as Interim CFO
03-Sep Allotment of shares by BBIL to Tata Capital
Aug-20
21-Aug Intimation pursuant to Regulation 30 of SEBI Listing Regulations, amendment in Memorandum of Association of the Company
Jul-20
25-Jul Voting results and scrutinizers’ report of the 42nd Annual General Meeting (‘AGM’) of Biocon Limited (‘the Company’)
25-Jul Proceedings of the 42nd Annual General Meeting (‘AGM’) of Biocon Limited (‘the Company’)
23-Jul Outcome of the Board Meeting
02-Jul Notice of 42nd Annual General Meeting and the Annual Report for the FY 2019-20.
May-20
14-May Outcome of the Board Meeting
14-May Appointment of Interim Chief Financial Officer (‘Interim CFO’) and Key Managerial Personnel of the Company
Jan-20
23-Jan  Outcome of the Board Meeting
ARCHIVES

FY: From April 1 – March 31

Know more
about us

>> Generics
>> Biocon Academy
>> Biocon Malaysia

NOVEL BIOLOGICS
BIOSIMILARS
RESEARCH SERVICES
OUR CULTURE
BIOCON FOUNDATION

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2025, Biocon. All Rights Reserved
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>